<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159158</url>
  </required_header>
  <id_info>
    <org_study_id>40331</org_study_id>
    <nct_id>NCT01159158</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition</brief_title>
  <official_title>RANDOMIZED, 2-WAY CROSSOVER, BIOEQUIVALENCE STUDY OF NATEGLINIDE 120 mg TABLET AND STARLIX@ ADMINISTERED AS 1 x 120 mg TABLET IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of nateglinide&#xD;
      120 mg tablet (test) versus Starlix Â® (reference), administered as 1 x 120 mg tablet under&#xD;
      fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single center, bioequivalence, open-label, randomized, 2-way crossover study. 64 + 4 healthy&#xD;
      adult male or female, smokers and/or non-smokers. Single oral dose (1 x 120 mg) in each&#xD;
      period with a washout of at least 7 days between doses. Dosing with 240 ml of glucose&#xD;
      solution (25%).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence on Cmax and AUC parameters</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Nateglinide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Starlix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Starlix Tablets 120 mg of Novartis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nateglinide</intervention_name>
    <description>Nateglinide Tablets 120 mg</description>
    <arm_group_label>Nateglinide</arm_group_label>
    <arm_group_label>Starlix</arm_group_label>
    <other_name>Starlix tablets 120 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, smoker or non-smoker, 18 years of age and older.&#xD;
&#xD;
          -  Capable of consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects to whom any of the following applies will be excluded from the study:&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks prior to the administration of the&#xD;
             study medication.&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior to the administration of the study&#xD;
             medication.&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.&#xD;
&#xD;
          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or&#xD;
             over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.&#xD;
&#xD;
          -  History of significant alcohol abuse within six months prior to the screening visit or&#xD;
             any indication of the regular use of more than fourteen units of alcohol per week (1&#xD;
             Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol),&#xD;
&#xD;
          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)&#xD;
             within 3 months prior to the screening visit or hard drugs (such as cocaine,&#xD;
             phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive&#xD;
             urine drug screen at screening.&#xD;
&#xD;
          -  History of allergic reactions to heparin, nateglinide, or other related drugs.&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole;&#xD;
             examples of inhibitors: antidepressant (SSRI), cimetidine, diltiazem, macrolides,&#xD;
             imidazoles, neuroleptics, verapamil fluoroquinolones, antihistamines) within 30 days&#xD;
             prior to administration of the study medication.&#xD;
&#xD;
          -  Use of an investigational drug or participation in an investigational study within 30&#xD;
             days prior to administration of the study medication.&#xD;
&#xD;
          -  Clinically significant history or presence of any clinically significant&#xD;
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),&#xD;
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney&#xD;
             disease, or other conditions known to interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of the drug.&#xD;
&#xD;
          -  Any clinically significant history or presence of clinically significant neurological,&#xD;
             endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or&#xD;
             metabolic disease.&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of study&#xD;
             medication or over-the-counter products (including natural food supplements, vitamins,&#xD;
             garlic as a supplement) within 7 days prior to administration of study medication,&#xD;
             except for topical products without systemic absorption or hormonal contraceptives.&#xD;
&#xD;
          -  Difficulty to swallow study medication.&#xD;
&#xD;
          -  Smoking more than 10 cigarettes per day.&#xD;
&#xD;
          -  Any food anergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             Medical Sub-Investigator, could contraindicate the subject's participation in this&#xD;
             study.&#xD;
&#xD;
          -  A depot injection or an implant of any drug (other than hormonal contraceptive) within&#xD;
             3 months prior to administration of study medication.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or&#xD;
             loss of whole blood (excluding the volume of blood that will be drawn during the&#xD;
             screening procedures of this study) prior to administration of the study medication as&#xD;
             follows:&#xD;
&#xD;
          -  50 mL to 300 mL of whole blood within 30 days,&#xD;
&#xD;
          -  301 mL to 500 mL of whole blood within 45 days, or&#xD;
&#xD;
          -  more than 500 mL of whole blood within 56 days prior to drug administration.&#xD;
&#xD;
          -  Consumption of food or beverages containing grapefruit (e.g. fresh, canned, or frozen)&#xD;
             within 7 days prior to administration of the study medication.&#xD;
&#xD;
          -  Patients affected by Type 1 diabetes or diabetic ketoacidosis (this last condition&#xD;
             should be treated with insulin).&#xD;
&#xD;
          -  Breast-feeding.&#xD;
&#xD;
          -  Positive serum pregnancy test at screening.&#xD;
&#xD;
          -  Female subjects of childbearing potential having unprotected sexual intercourse with&#xD;
             any non-sterile male partner within 14 days prior to study drug administration.&#xD;
             Acceptable methods of contraception:&#xD;
&#xD;
          -  condom + spermicide;&#xD;
&#xD;
          -  diaphragm + spermicide;&#xD;
&#xD;
          -  intra-uterine contraceptive device (placed at least 4 weeks prior to study drug&#xD;
             administration);&#xD;
&#xD;
          -  hormonal contraceptives (starting at least 4 weeks prior to study drug&#xD;
             administration).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio R Pizarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC International, SFBC Miami, Inc. 11190 Biscayne Blvd.Miami, Fl 33181, USA</affiliation>
  </overall_official>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <last_update_submitted>July 12, 2010</last_update_submitted>
  <last_update_submitted_qc>July 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Vice president- Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nateglinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

